Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 15, 2015 - Issue 3
Submit an article Journal homepage
443
Views
41
CrossRef citations to date
0
Altmetric
Review

Building a roadmap for developing combination therapies for Alzheimer’s disease

Daniel PerryAlliance for Aging Research, Washington, DC, USA
,
Reisa SperlingHarvard Medical School Brigham and Women’s Hospital, Boston, MA, USA
,
Russell KatzUS FDA Retired, San Diego, CA, USA
,
Donald BerryMD Anderson Cancer Center, Houston, TX, USA
,
David DiltsOregon Health and Science University, Portland, OR, USA
,
Debra HannaCritical Path Institute, Tucson, AZ, USA
,
Stephen SallowayBrown University Butler Hospital, Providence, RI, USA
,
John Q TrojanowskiDepartment Pathol and Lab Med, University of Pennsylvania, School of Medicine, Alzheimers Dis Core Ctr, Ctr Neurodegenerat Dis Res, Inst Ageing, Philadelphia, PA, USA
,
Chas BountraUniversity of Oxford, Headington, UK
,
Michael KramsJanssen Pharmaceuticals, Philadelphia, PA, USA
,
Johan LuthmanEisai, Philadelphia, PA, USA
,
Steven PotkinUniversity of California Irvine, Irvine, CA, USA
,
Val GribkoffElan, South San Francisco, CA, USA
,
Robert TempleUS FDA, Silver Spring, MD, USA
,
Yaning WangUS FDA, Silver Spring, MD, USA
,
Maria C CarrilloAlzheimer’s Association, Chicago, IL, USA
,
Diane StephensonCritical Path Institute, Tucson, AZ, USA
,
Heather SnyderAlzheimer’s Association, Chicago, IL, USA
,
Enchi LiuJanssen Pharmaceuticals, South San Francisco, CA, USA
,
Tony WareEli Lilly, Indianapolis, IN, USA
,
John McKewNational Institutes of Health, Bethesda, MD, USA
,
F Owen FieldsPfizer, Philadelphia, PA, USA
,
Lisa J BainPhiladelphia, PA, USA
&
Cynthia BensAlliance for Aging Research, Washington, DC, USACorrespondence[email protected]
 show all
Pages 327-333 | Published online: 23 Feb 2015

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ramón Cacabelos. (2018) Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?. Expert Opinion on Drug Discovery 13:6, pages 523-538.
Read now

Articles from other publishers (40)

Md. Ashrafur Rahman, Arif Anzum Shuvo, Md. Mehedi Hasan Apu, Monisha Rani Bhakta, Farzana Islam, Md. Atiqur Rahman, Md. Rabiul Islam & Hasan Mahmud Reza. (2023) Combination of epigallocatechin 3 gallate and curcumin improves d-galactose and normal-aging associated memory impairment in mice. Scientific Reports 13:1.
Crossref
Yu Chen, Samira Pal & Quanyin Hu. (2023) Cell-based relay delivery strategy in biomedical applications. Advanced Drug Delivery Reviews 198, pages 114871.
Crossref
Aditya Singh, Vaseem Ahamad Ansari, Tarique Mahmood Ansari, Syed Misabah Hasan, Farogh Ahsan, Kuldeep Singh, Rufaida Wasim, Shubhrat Maheshwari & Asad Ahmad. (2023) Consequence of Dementia and Cognitive Impairment by Primary Nucleation Pathway. Hormone and Metabolic Research 55:05, pages 304-314.
Crossref
João Pedro Ferrari-Souza & Lucas Porcello Schilling. (2023) Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer. PAJAR - Pan-American Journal of Aging Research 11:1, pages e44542.
Crossref
George D. Wilson, C. Leland Rogers, Minesh P. Mehta, Brian Marples, Daniel B. Michael, James S. Welsh, Alvaro A. Martinez & James Fontanesi. (2023) The Rationale for Radiation Therapy in Alzheimer's Disease. Radiation Research 199:5.
Crossref
Guillaume Blivet, Aroa Relano-Gines, Mélanie Wachtel & Jacques Touchon. (2022) A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance. Journal of Alzheimer's Disease 90:2, pages 811-822.
Crossref
Arash Salehipour, Motahareh Bagheri, Mohammadmahdi Sabahi, Mahsa Dolatshahi & Delphine Boche. (2022) Combination Therapy in Alzheimer’s Disease: Is It Time?. Journal of Alzheimer's Disease 87:4, pages 1433-1449.
Crossref
Mengmeng Sang, Ang Dong, Shuang Wu, Feng Li, Jing Wang, Christopher Griffin & Rongling Wu. (2022) A graph model of combination therapies. Drug Discovery Today 27:5, pages 1210-1217.
Crossref
Jonathan Janssens, Bart Hermans, Marc Vandermeeren, Erio Barale-Thomas, Marianne Borgers, Roland Willems, Greet Meulders, Cindy Wintmolders, Dries Van den Bulck, Astrid Bottelbergs, Luc Ver Donck, Peter Larsen, Dieder Moechars, Wilson Edwards, Marc Mercken & Bianca Van Broeck. (2021) Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. Neurobiology of Disease 154, pages 105365.
Crossref
Mrinal K. Poddar, Soumyabrata Banerjee, Apala Chakraborty & Debasmita Dutta. (2021) Metabolic disorder in Alzheimer’s disease. Metabolic Brain Disease 36:5, pages 781-813.
Crossref
Thomas J Anastasio. (2021) Predicting the Potency of Anti-Alzheimer’s Drug Combinations Using Machine Learning. Processes 9:2, pages 264.
Crossref
Marcela Kitaigorodsky, Elizabeth Crocco, Rosie E. Curiel‐Cid, Giselle Leal, Diane Zheng, Melissa K. Eustache, Maria T. Greig‐Custo, William Barker, Ranjan Duara & David A. Loewenstein. (2021) The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 13:1.
Crossref
Shikha Goswami, Ozaifa Kareem, Ramesh K. Goyal, Sayed M. Mumtaz, Rajiv K. Tonk, Rahul Gupta & Faheem H. Pottoo. (2020) Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer’s Disease. CNS & Neurological Disorders - Drug Targets 19:9, pages 709-721.
Crossref
Jerzy Leszek, Elizaveta V. Mikhaylenko, Dmitrii M. Belousov, Efrosini Koutsouraki, Katarzyna Szczechowiak, Małgorzata Kobusiak-Prokopowicz, Andrzej Mysiak, Breno Satler Diniz, Siva G. Somasundaram, Cecil E. Kirkland & Gjumrakch Aliev. (2020) The Links between Cardiovascular Diseases and Alzheimer's Disease. Current Neuropharmacology 19:2, pages 152-169.
Crossref
Eli J. Cornblath, John L. Robinson, David J. Irwin, Edward B. Lee, Virginia M.-Y. Lee, John Q. Trojanowski & Danielle S. Bassett. (2020) Defining and predicting transdiagnostic categories of neurodegenerative disease. Nature Biomedical Engineering 4:8, pages 787-800.
Crossref
Anne Vinther Morant, Henrik Tang Vestergaard, Anders Blædel Lassen & Vaidrius Navikas. (2020) US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development. Clinical and Translational Science 13:4, pages 652-664.
Crossref
Somin Kwon, Michiyo Iba, Changyoun Kim & Eliezer Masliah. (2020) Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets. Neurotherapeutics 17:3, pages 935-954.
Crossref
Daniela J. Conrado, Sridhar Duvvuri, Hugo Geerts, Jackson Burton, Carla Biesdorf, Malidi Ahamadi, Sreeraj Macha, Gregory Hather, Juan Francisco Morales, Jagdeep Podichetty, Timothy Nicholas, Diane Stephenson, Mirjam Trame, Klaus Romero & Brian Corrigan. (2020) Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Clinical Pharmacology & Therapeutics 107:4, pages 796-805.
Crossref
Alberto J. Espay, Lorraine V. KaliaZiv Gan-OrCaroline H. Williams-GrayPhilippe L. Bedard, Steven M. RoweFrancesca MorganteAlfonso FasanoBenjamin StecherMarcelo A. KauffmanMatthew J. Farrer, Chris S. CoffeyMichael A. SchwarzschildTodd ShererRonald B. PostumaAntonio P. StrafellaAndrew B. SingletonRoger A. BarkerKarl KieburtzC. Warren OlanowAndres LozanoJeffrey H. KordowerJesse M. CedarbaumPatrik BrundinDavid G. Standaert & Anthony E. Lang. (2020) Disease modification and biomarker development in Parkinson disease. Neurology 94:11, pages 481-494.
Crossref
Fares Bassil, Hannah J. Brown, Shankar Pattabhiraman, Joe E. Iwasyk, Chantal M. Maghames, Emily S. Meymand, Timothy O. Cox, Dawn M. Riddle, Bin Zhang, John Q. Trojanowski & Virginia M.-Y. Lee. (2020) Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology. Neuron 105:2, pages 260-275.e6.
Crossref
Yu Wan, Yingxia Liang, Feng Liang, Nolan Shen, Kenneth Shinozuka, Jin-Tai Yu, Chongzhao Ran, Qimin Quan, Rudolph E. Tanzi & Can Zhang. (2019) A Curcumin Analog Reduces Levels of the Alzheimer’s Disease-Associated Amyloid-β Protein by Modulating AβPP Processing and Autophagy. Journal of Alzheimer's Disease 72:3, pages 761-771.
Crossref
Mariam B. Camacho, Warut D. Vijitbenjaronk & Thomas J. Anastasio. (2019) Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems. Frontiers in Pharmacology 10.
Crossref
Diane T. Stephenson & Stephen P. Arnerić. 2019. Translational Medicine in CNS Drug Development. Translational Medicine in CNS Drug Development 277 296 .
David A. LoewensteinRosie E. CurielSteven DeKoskyRussell M. BauerMonica RosselliSalvador M. GuinjoanMalek AdjouadiAilyn PeñateWilliam W. BarkerSindy GoenagaTodd GoldeMaria T. Greig-CustoKevin S. HansonChunfei LiGabriel LizarragaMichael MarsiskeRanjan Duara. (2018) Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment. Neurology 91:10.
Crossref
John L Robinson, Edward B Lee, Sharon X Xie, Lior Rennert, EunRan Suh, Colin Bredenberg, Carrie Caswell, Vivianna M Van Deerlin, Ning Yan, Ahmed Yousef, Howard I Hurtig, Andrew Siderowf, Murray Grossman, Corey T McMillan, Bruce Miller, John E Duda, David J Irwin, David Wolk, Lauren Elman, Leo McCluskey, Alice Chen-Plotkin, Daniel Weintraub, Steven E Arnold, Johannes Brettschneider, Virginia M.-Y Lee & John Q Trojanowski. (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141:7, pages 2181-2193.
Crossref
Angie C.A. Chiang, Stephanie W. Fowler, Ricky R. Savjani, Susan G. Hilsenbeck, Clare E. Wallace, John R. Cirrito, Pritam Das & Joanna L. Jankowsky. (2018) Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. Journal of Experimental Medicine 215:5, pages 1349-1364.
Crossref
Anthony E. Lang & Alberto J. Espay. (2018) Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders 33:5, pages 660-677.
Crossref
Rudimar L. Frozza, Mychael V. Lourenco & Fernanda G. De Felice. (2018) Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience 12.
Crossref
Jason Weller & Andrew Budson. (2018) Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research 7, pages 1161.
Crossref
Ludger WeßFrank Schnieders. (2017) Immuno-Oncology—The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets. Human Gene Therapy 28:12, pages 1130-1137.
Crossref
Valentin K. Gribkoff & Leonard K. Kaczmarek. (2017) The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120, pages 11-19.
Crossref
Anne-Sophie Cornec, Ludovica Monti, Jane Kovalevich, Vishruti Makani, Michael J. James, Krishna G. Vijayendran, Killian Oukoloff, Yuemang Yao, Virginia M.-Y. Lee, John Q. Trojanowski, Amos B. SmithIIIIII, Kurt R. Brunden & Carlo Ballatore. (2017) Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases. Journal of Medicinal Chemistry 60:12, pages 5120-5145.
Crossref
Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Robert C. Green, Danielle Harvey, Clifford R. JackJr.Jr., William Jagust, John C. Morris, Ronald C. Petersen, Jennifer Salazar, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga & John Q. Trojanowski. (2016) The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's & Dementia 13:5, pages 561-571.
Crossref
R Derungs, G G Camici, R D Spescha, T Welt, C Tackenberg, C Späni, F Wirth, A Grimm, A Eckert, R M Nitsch & L Kulic. (2016) Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer’s disease. Molecular Psychiatry 22:4, pages 605-614.
Crossref
C. Walsh, W.H.I.M. Drinkenburg & A. Ahnaou. (2017) Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews 73, pages 340-358.
Crossref
Randall J. Bateman, Tammie L. Benzinger, Scott Berry, David B. Clifford, Cynthia Duggan, Anne M. Fagan, Kathleen Fanning, Martin R. Farlow, Jason Hassenstab, Eric M. McDade, Susan Mills, Katrina Paumier, Melanie Quintana, Stephen P. Salloway, Anna Santacruz, Lon S. Schneider, Guoqiao Wang & Chengjie Xiong. (2016) The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's & Dementia 13:1, pages 8-19.
Crossref
Jeffrey Cummings, Travis Morstorf & Garam Lee. (2016) Alzheimer's drug-development pipeline: 2016. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2:4, pages 222-232.
Crossref
Mansi R. Khanna, Jane Kovalevich, Virginia M.‐Y. Lee, John Q. Trojanowski & Kurt R. Brunden. (2016) Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer's & Dementia 12:10, pages 1051-1065.
Crossref
James A. Hendrix, Randall J. Bateman, H. Robert Brashear, Cynthia Duggan, Maria C. Carrillo, Lisa J. Bain, Ronald DeMattos, Russell G. Katz, Susanne Ostrowitzki, Eric Siemers, Reisa Sperling & Ottavio V. Vitolo. (2016) Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. Alzheimer's & Dementia 12:5, pages 623-630.
Crossref
Bradford C. Dickerson, Federica Agosta & Massimo Filippi. 2016. fMRI Techniques and Protocols. fMRI Techniques and Protocols 699 739 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.